3d
Zacks Investment Research on MSNSage Therapeutics (SAGE) Up 7.4% Since Last Earnings Report: Can It Continue?A month has gone by since the last earnings report for Sage Therapeutics, Inc. (SAGE). Shares have added about 7.4% in that time frame, outperforming the S&P 500. Will the recent positive trend ...
South Side-based biotech firm Carmell Corp. announced a comprehensive corporate rebrand and will now operate under the new ...
John "Chip" Scarlett, who as chairman, president and CEO repositioned Geron Corp. and guided the company to its first drug ...
Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results